Detalles de la búsqueda
1.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 19(6): 799-811, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29753703
2.
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Oncologist
; 23(10): 1133-e112, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30076277
3.
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Int J Cancer
; 132(11): 2557-66, 2013 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23151995
4.
[Endo-arthroscopically assisted surgery of selected orthopaedic conditions: technique and results]. / Chirurgia mini-invasiva articolare ed extra-articolare assistita dall'endoscopia. Tecniche e risultati in patologia ortopedica.
Ann Ital Chir
; 77(4): 329-33, 2006.
Artículo
en Italiano
| MEDLINE | ID: mdl-17139963
5.
Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory.
Sci Transl Med
; 7(317): 317ra198, 2015 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26659572
6.
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Eur J Radiol
; 80(3): 655-61, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20863638
7.
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Clin Cancer Res
; 17(7): 1964-72, 2011 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21307147
8.
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Eur J Cancer
; 46(15): 2746-52, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20708923
9.
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
Clin Cancer Res
; 16(4): 1315-23, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20145168
10.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Eur J Cancer
; 46(1): 198-206, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19900802
11.
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
J Clin Oncol
; 28(15): 2604-11, 2010 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-20406925
12.
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Breast Cancer Res Treat
; 101(3): 355-65, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16850247
13.
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Cancer
; 97(5): 1174-80, 2003 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12599222
14.
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Cancer
; 100(2): 279-87, 2004 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14716761
Resultados
1 -
14
de 14
1
Próxima >
>>